Expand all sections

Avelumab

Bavencio

Extended indication Treatment of locally advanced unresectable, metastatic or recurrent non-small cell lung cancer (NSCL
Therapeutic value No judgement
Total cost 22,050,000.00
Registration phase Withdrawn

Product

Active substance Avelumab
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Treatment of locally advanced unresectable, metastatic or recurrent non-small cell lung cancer (NSCLC) after prior chemotherapy in adults, 2L.
Proprietary name Bavencio
Manufacturer Merck
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks PD-L1 remmer. Betreft een samenwerking tussen Merck en Pfizer.

Registration

Registration route Centralised (EMA)
Particularity Indication extension
Orphan drug No
Registration phase Withdrawn
Additional remarks Fabrikant geeft aan dat het ontwikkelingsprogramma is gestaakt.

Therapeutic value

Current treatment options Nivolumab, Pembrolizumab, Atezolizumab
Therapeutic value No judgement
Frequency of administration 2 times a month
Dosage per administration 10 mg/kg
References Fabrikant; NCT02395172
Additional remarks Toediningsfrequentie: 1 maal per 2 weken

Expected patient volume per year

Patient volume

308 - 574

Market share is generally not included unless otherwise stated.
References Pakketadvies Pembrolizumab
Additional remarks Patiëntvolume is vergelijkbaar met Pembrolizumab/Nivolumab voor deze indicatie. Beoordeling Zorginstituut Pembrolizumab: Max. patiëntvolume: 1.230-2.295; Realistisch patiëntvolume: 308-574 (1/4 van max. volume).

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks €979,72 per 20 mg/ml voor 10 ml flacon.

Potential total cost per year

Total cost

22,050,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No

Indication extension

Indication extension Yes
Indication extensions Ovarium 2L (2H 2019), RCC 1L (2020)
References Fabrikant

Other information

There is currently no futher information available.